GlassScriptPhysician profile
Rolando Posada
NPI 1578526091
$3,384.47
in general payments reported to CMS, 2019-2025
30 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $416 · 2021: $507 · 2022: $417 · 2023: $707 · 2024: $639 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.05 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $816.08 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $328.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $224.48 | 2021-2025 | |
| Revance Therapeutics, INC. | $213.74 | 2024-2025 | Daxi, Daxxify |
| Horizon Therapeutics Plc | $187.76 | 2019-2023 | Krystexxa |
| Astellas Pharma US INC | $178.75 | 2020-2024 | Veozah |
| Merz North America, INC. | $172.02 | 2023-2024 | Xeomin |
| Galderma Laboratories, L.P. | $145.58 | 2022 | |
| Sanofi-Aventis U.S. LLC | $131.55 | 2020-2023 | |
| Pfizer INC. | $125.42 | 2020-2021 | |
| Allergan, INC. | $119.45 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.45 | 2023 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $64.16 | 2021-2023 | Trelegy Ellipta |
| Amgen INC. | $63.76 | 2019-2025 | Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $63.19 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $62.31 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $60.27 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $52.92 | 2019-2020 | |
| Exact Sciences Corporation | $44.83 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $40.39 | 2020-2021 | |
| Medtronic USA, INC. | $37.26 | 2019 | |
| Dexcom, INC. | $32.57 | 2021-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $28.95 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $28.19 | 2021-2022 | |
| Lundbeck LLC | $20.16 | 2025 | Rexulti |
| Antares Pharma, INC. | $17.90 | 2024 | Xyosted |
| Phadia US INC. | $17.72 | 2025 | Immunocap |
| Hologic Sales and Service, LLC | $15.93 | 2025 | Aptima |
| Astrazeneca Pharmaceuticals LP | $13.40 | 2024 | Farxiga |
| Si-Bone, INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolando Posada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.